Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
复制标题
DOI：
10.1016/j.leukres.2014.03.004
复制
发表时间：
2014-07-01
影响因子：
2.7
通讯作者：
Sanz, Guillermo
中科院分区：
文献类型：
--
作者：
Garcia-Delgado, Regina;de Miguel, Dunia;Sanz, Guillermo
我们研究了阿扎替丁对世界卫生组织定义的骨髓增生异常综合征或具有20-30%骨髓母细胞的急性髓系白血病患者的有效性和耐受性。患者接受阿扎替丁治疗，用三种剂量方案之一：5天(AZA 5)；7天(含2天休息)(AZA 5-2-2)；或7天(AZA 7)；所有28天周期。总有效率分别为39.4%、67.9%和51.3%，中位总生存期分别为13.2、19.1和14.9个月。中性粒细胞减少是最常见的3-4级不良事件。这些结果表明，7天计划的有效性-耐受性更好。(C)2014年提交人。爱思唯尔有限公司出版。
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. (C) 2014 The Authors. Published by Elsevier Ltd.